P0168 : The impact on hospital resource utilisation of Rifaximin-α(alpha) for hepatic encephalopathy in routine clinical practice: Real world data from seven UK liver centres

http://dx.doi.org/10.1016/S0168-8278(15)30387-1

Post author By Orr J G, Goel A, Moriaty K J, Sinha A, Gordon F H, Dethier A, Dillon J F, Patel V, Shawcross D L, Clark K, Richardson P, Preedy H, Aspinall R J, Currie C J and Hudson M
Post date 1 April 2015

Orr J G, Goel A, Moriarty K, Sinha A, Gordon F H, Dethier A, Dillon J, Patel V, Shawcross D L, Clark K, Richardson P, Preedy H, Aspinall R, Currie C J, Hudson M. 01 Apr 2015

Orr J G

Goel A

Moriaty K J

Sinha A

Gordon F H

Dethier A

Dillon J F

Patel V

Shawcross D L

Clark K

Richardson P

Preedy H

Aspinall R J

Currie C J

Hudson M

Transforming real-world data into transparent, reliable, and reliable real-world evidence

44 (0) 2920 782856

enquiries@humandatasciences.com

24 Wordsworth Avenue, Cardiff, CF24 3FR United Kingdom

Copyright Pharmatelligence Limited (trading as Human Data Sciences) is a Private Limited Company (PLC) registered in England and Wales with Company Number 7107514.

Livingstone® is a Trusted Research Environment (TRE)

Quick Links

Transforming real-world data into transparent, reliable, and replicable real-world evidence

44 (0) 2920 782856

instantRWE@humandatasciences.com

The Global Pharma Research Centre,
24 Wordsworth Avenue, Cardiff, CF24 3FR United Kingdom

Copyright Pharmatelligence Limited (trading as Human Data Sciences) is a Private Limited Company (PLC) registered in England and Wales with Company Number 7107514.

Livingstone^® is a Trusted Research Environment (TRE)

Web Design – Create Summit

Site by Create Summit